Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).
Joanna C ThornEmma L TurnerEleanor I WalshJenny L DonovanDavid E NealFreddie C HamdyRichard M MartinSian M NoblePublished in: BMC health services research (2023)
Introducing a single PSA screening test for men aged 50-69 across England and Wales could lead to very high initial secondary-care costs.